These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


923 related items for PubMed ID: 15364810

  • 1. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA.
    Circulation; 2004 Sep 21; 110(12):1572-8. PubMed ID: 15364810
    [Abstract] [Full Text] [Related]

  • 2. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators.
    Circulation; 2005 Nov 29; 112(22):3391-9. PubMed ID: 16301343
    [Abstract] [Full Text] [Related]

  • 3. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 21; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 5. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 6. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA.
    Circulation; 2005 Jun 28; 111(25):3411-9. PubMed ID: 15967846
    [Abstract] [Full Text] [Related]

  • 7. High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Anderson RE, Pfeffer MA, Thune JJ, McMurray JJ, Califf RM, Velazquez E, White HD, Rouleau JL, Skali H, Maggioni A, Solomon SD.
    Am Heart J; 2008 Apr 28; 155(4):706-11. PubMed ID: 18371480
    [Abstract] [Full Text] [Related]

  • 8. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
    Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA.
    N Engl J Med; 2004 Sep 23; 351(13):1285-95. PubMed ID: 15385655
    [Abstract] [Full Text] [Related]

  • 9. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S, Davis BR, Braunwald E, Rouleau JL, Dagenais GR, Sussex B, Steingart RM, Brown EJ, Lamas GA, Gordon D, Bernstein V, Pfeffer MA, Survival and Ventricular Enlargement Trial.
    Am Heart J; 2004 Aug 23; 148(2):356-64. PubMed ID: 15309009
    [Abstract] [Full Text] [Related]

  • 10. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 11. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Reed SD, McMurray JJ, Velazquez EJ, Schulman KA, Califf RM, Kober L, Maggioni AP, Van de Werf F, White HD, Diaz R, Mareev V, Murin J, VALIANT Committees and Investigators.
    Am Heart J; 2006 Sep 20; 152(3):500-8. PubMed ID: 16923421
    [Abstract] [Full Text] [Related]

  • 12. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
    Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD, VALsartan In Acute myocardial iNfarcTion (VALIANT) Trial Investigators.
    Am Heart J; 2010 Jul 20; 160(1):145-51. PubMed ID: 20598985
    [Abstract] [Full Text] [Related]

  • 13. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM, Hennekens CH, Lamas GA, Jiménez-Navarro M, Rouleau JL, Flaker GC, Goldman S, Skali H, Braunwald E, Pfeffer MA.
    Arch Intern Med; 2004 Nov 08; 164(20):2273-9. PubMed ID: 15534166
    [Abstract] [Full Text] [Related]

  • 14. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, VALIANT Investigators.
    Am Heart J; 2005 Aug 08; 150(2):323-9. PubMed ID: 16086938
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
    Stephenson K, Skali H, McMurray JJ, Velazquez EJ, Aylward PG, Kober L, Van de Werf F, White HD, Pieper KS, Califf RM, Solomon SD, Pfeffer MA.
    Heart Rhythm; 2007 Mar 08; 4(3):308-13. PubMed ID: 17341394
    [Abstract] [Full Text] [Related]

  • 16. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
    Moukarbel GV, Signorovitch JE, Pfeffer MA, McMurray JJ, White HD, Maggioni AP, Velazquez EJ, Califf RM, Scheiman JM, Solomon SD.
    Eur Heart J; 2009 Sep 08; 30(18):2226-32. PubMed ID: 19556260
    [Abstract] [Full Text] [Related]

  • 17. Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus.
    Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R, White H, Kober L, Velazquez E, Pfeffer MA.
    Am J Cardiol; 2008 Apr 01; 101(7):925-9. PubMed ID: 18359309
    [Abstract] [Full Text] [Related]

  • 18. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
    Thomas KL, Al-Khatib SM, Lokhnygina Y, Solomon SD, Kober L, McMurray JJ, Califf RM, Velazquez EJ.
    Am Heart J; 2008 Jan 01; 155(1):87-93. PubMed ID: 18082495
    [Abstract] [Full Text] [Related]

  • 19. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
    Køber L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau JL, Leimberger JD, Califf RM.
    Eur J Heart Fail; 2006 Oct 01; 8(6):591-8. PubMed ID: 16507350
    [Abstract] [Full Text] [Related]

  • 20. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
    Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, Velazquez E, Califf R, Pfeffer MA, Solomon SD.
    Eur J Heart Fail; 2011 Feb 01; 13(2):148-53. PubMed ID: 21037250
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 47.